How has CorMedix's payments to acquire short-term investments changed year-over-year?

CorMedix's payments to acquire short-term investments decreased by 100.0% year-over-year, from $9.99M to $0.

CorMedix CRMD Payments to Acquire Short-Term Investments

Payments to Acquire Short-Term Investments at other companies

PfizerPFE

——

Rigel PharmaceuticalsRIGL

——

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's payments to acquire short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's payments to acquire short-term investments?: CorMedix (CRMD) reported payments to acquire short-term investments of $0 in Q1 2026.
How has CorMedix's payments to acquire short-term investments changed year-over-year?: CorMedix's payments to acquire short-term investments decreased by 100.0% year-over-year, from $9.99M to $0.